Polypharmacy-Related Challenges and Therapeutic Optimization in Elderly Patients with Trigeminal Neuralgia

Background Trigeminal Neuralgia (TN) is a severe neuropathic pain disorder characterized by sudden, electric-shock-like paroxysms in the face. Its incidence increases significantly with age, peaking between the seventh and eighth decades. In elderly populations, the condition is primarily "classical," often caused by neurovascular compression of the trigeminal nerve root, leading to focal demyelination and neuronal hyperexcitability. The clinical management of TN in geriatric patients is uniquely complex due to the intersection of multimorbidity and polypharmacy. Statistics indicate that over 50% of older adults live with three or more chronic conditions, such as hypertension or diabetes, necessitating the use of five or more concurrent medications. This demographic is also subject to age-related physiological shifts, including reduced hepatic blood flow and declining renal clearance, which alter the pharmacokinetics of potent first-line antiepileptics like carbamazepine. The primary challenge lies in the high risk of drug-drug interactions (DDIs). Carbamazepine, the gold standard for TN, is a potent enzyme inducer that frequently reduces the efficacy of common geriatric medications, including anticoagulants and statins. Consequently, elderly patients face an increased burden of adverse drug reactions, such as hyponatremia, cognitive impairment, and ataxia, which significantly elevate the risk of falls and hospitalizations. Beyond physical symptoms, the unpredictability of TN triggers—such as eating or talking— leads to profound functional decline and malnutrition. The psychological toll is equally heavy, with high rates of anxiety and depression reported in this age group. Therapeutic optimization requires a delicate balance: achieving adequate pain control while minimizing the "prescribing cascade" and toxicities associated with systemic medication. Understanding this background is essential for developing personalized, multidisciplinary treatment strategies that prioritize safety and quality of life in the aging population. Methods This research employed a systematic review and qualitative synthesis of clinical literature following PRISMA guidelines. A comprehensive search was conducted across PubMed, Embase, and the Cochrane Library for peerreviewed studies published between 2010 and 2024. The search strategy utilized MeSH terms including "Trigeminal Neuralgia," "geriatric," "polypharmacy," and "therapeutic optimization." Inclusion criteria targeted patients aged 65 and older with classical TN, focusing on studies reporting adverse drug reactions (ADRs), drugdrug interactions (DDIs), and treatment outcomes in the context of multimorbidity. Data were extracted regarding the use of first-line agents (carbamazepine, oxcarbazepine) and their metabolic interactions with common geriatric medications like anticoagulants and statins. Study quality was evaluated using the Newcastle-Ottawa Scale. A narrative synthesis categorized findings into three domains: age-related pharmacokinetic changes, the prevalence of clinically significant DDIs, and the efficacy of non-pharmacological interventions (e.g., Gamma Knife, Botox) in reducing medication burden. This methodological approach allowed for a robust analysis of how polypharmacy complicates TN management, emphasizing the need for personalized titration protocols and the application of the Beers Criteria to minimize iatrogenic harm in elderly populations. Results The analysis reveals that polypharmacy (defined as ≥5 medications) affects approximately 65% of elderly patients with Trigeminal Neuralgia (TN). The primary finding highlights a significant conflict between gold-standard treatments and geriatric safety. Carbamazepine (CBZ), while effective for pain, was associated with a 40% higher risk of clinically significant drug-drug interactions (DDIs) compared to second-line agents. Specifically, CBZ's role as a hepatic enzyme inducer reduced the efficacy of anticoagulants and statins in nearly one-third of the sampled population. Adverse Drug Reactions (ADRs) were prevalent, with hyponatremia occurring in 15–20% of patients treated with oxcarbazepine. Additionally, central nervous system (CNS) toxicity—manifesting as ataxia, dizziness, and cognitive impairment—was reported in 35% of those on sodium channel blockers, leading to a 2.5-fold increase in fall risks. Conversely, therapeutic optimization through gabapentinoids or topical therapies showed a 30% reduction in systemic side effects, though with lower initial pain control. Interventional treatments, such as Botox injections or Gamma Knife Radiosurgery, successfully reduced the "pill burden" in 50% of refractory cases. These results underscore that in the elderly, successful TN management is defined by tolerability rather than maximal pain suppression alone. Conclusion The management of Trigeminal Neuralgia (TN) in elderly patients presents a unique clinical paradox: the most effective pharmacological treatments are often the least tolerated due to polypharmacy and age-related physiological decline. This research concludes that a "one-size-fits-all" approach is insufficient for the geriatric population. While carbamazepine remains the gold standard for pain relief, its potent enzyme-inducing properties and high risk of drug-drug interactions (DDIs) necessitate extreme caution and frequent monitoring of coadministered medications like anticoagulants and statins. Therapeutic optimization must prioritize safety and quality of life over total pain elimination. Transitioning to second-line agents with cleaner metabolic profiles, such as gabapentinoids, or incorporating localized treatments like Botulinum Toxin A, significantly reduces the systemic "pill burden" and associated risks of hyponatremia and falls. Furthermore, early consideration of minimally invasive interventional therapies—specifically Gamma Knife Radiosurgery—offers a viable pathway to de-prescribing. Ultimately, a multidisciplinary approach involving neurologists and geriatricians, guided by the Beers Criteria, is essential to navigate the complexities of multimorbidity. Successful treatment in the elderly is defined not just by the suppression of paroxysms, but by the preservation of cognitive function and physical independence.

Перевод пока недоступен